Pharmaceuticals Lonza grows strongly after takeover
Lonza is back in growth mode. The pharmaceutical supplier made strong gains in 2025, not least thanks to the purchase of a large production facility from Roche in California.
28.01.2026, 06:57
SDA
Lonza's sales from continuing operations rose by 19.2 percent to 6.53 billion Swiss francs, as the company announced on Wednesday. In the previous year, the loss of the large Moderna order for the coronavirus vaccination had still caused the company problems.
The takeover of the former Roche plant was one of the main drivers of sales. Without the Vacaville site, growth would have been in the low tens of percent range, explained Lonza.
At plus 24.9 percent to 2.06 billion Swiss francs, operating profit ("core EBITDA") rose even more strongly than sales. The margin increased accordingly from 30.2 to 31.6 percent.
At the end of the income statement, net profit amounted to CHF 909 million, compared to CHF 602 million in the previous year. The dividend is to rise by one franc to 5 francs per share.
Lonza did not comment further in the press release on the separation from the Capsules & Health Ingredients (CHI) division announced at the end of 2024.
In 2026, Lonza expects sales growth in local currencies of 11 to 12 percent in its core business. And the core EBITDA margin to rise to over 32 percent.
